RxDoctor Payments Data

Noel Garcia, MD

Internal Medicine · Houston, MSNPI 1053322842

Payments from drug & device makers

$2,280in general payments, 2019–2025

Across 151 payments — averaging $15.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$463
  • Lilly USA, LLC$375
  • Pfizer$284
  • Amgen$126
  • Boehringer Ingelheim$105
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$85
  • plus $841 from 24 others

What the payments were for

  • Food & beverage$2,271100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,280 in reported general payments places this provider in the 75th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$164,548
Medicare patients
287
Services billed
4,540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide264$416,142
OzempicSemaglutide234$289,819
EliquisApixaban197$144,125
JardianceEmpagliflozin81$106,060
TrulicityDulaglutide72$101,079
LinzessLinaclotide99$80,631
CreonLipase/Protease/Amylase54$53,957
RybelsusSemaglutide21$39,923
FarxigaDapagliflozin Propanediol35$37,378
QuliptaAtogepant23$34,531
KerendiaFinerenone25$31,374
XareltoRivaroxaban33$30,742
MovantikNaloxegol Oxalate60$27,914
Tresiba Flextouch U-100Insulin Degludec32$23,823
JanuviaSitagliptin Phosphate20$22,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$375$517,221336 claims
Novo NordiskOzempic, Rybelsus$16$329,742255 claims
AbbVieLinzess, Creon, Qulipta, Vraylar, Ubrelvy$463$211,445270 claims
PfizerEliquis$284$144,125197 claims
Boehringer IngelheimJardiance, Stiolto Respimat$105$113,27494 claims
AstraZenecaFarxiga, Symbicort, Brilinta$44$54,08087 claims
Johnson & JohnsonXarelto$76$30,74233 claims
NovartisEntresto$48$13,23118 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$11$6,62712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Houston

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →